Drug interactions
Lomitapide + Rimegepant
Severity: Moderate
Lomitapide and Rimegepant: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lomitapide inhibits P-glycoprotein and may increase rimegepant exposure. The effect is expected to be modest.
What this interaction means in plain words
Lomitapide and Rimegepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Lomitapide belongs to Cardiovascular; Rimegepant belongs to Central Nervous System.
Why it happens
Inhibition of P-glycoprotein efflux of rimegepant.
What to do
Avoid a repeat rimegepant dose within 48 hours and monitor tolerability.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lomitapide and Rimegepant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Rimegepant
Other interactions of Lomitapide
- Aprepitant + Lomitapide Contraindicated
- Clarithromycin + Lomitapide Contraindicated
- Crizotinib + Lomitapide Contraindicated
- Diltiazem + Lomitapide Contraindicated
- Efavirenz + Lomitapide Contraindicated
- Ensitrelvir + Lomitapide Contraindicated
Frequently asked questions
Can I take Lomitapide with Rimegepant?
MediHelp rates the interaction as moderate. Lomitapide and Rimegepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lomitapide inhibits P-glycoprotein and may increase rimegepant exposure. The effect is expected to be modest.
How serious is the interaction between Lomitapide and Rimegepant?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid a repeat rimegepant dose within 48 hours and monitor tolerability.
What other medicines interact with Rimegepant?
MediHelp also lists interactions of Rimegepant with, for example, Amobarbital, Atazanavir, Butabarbital. The full list is on the Rimegepant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
